Embedded Files
Self-harm has risen 400% since 2000, yet detection still relies largely on subjective judgement and risk too often stays invisible until crisis. NeuroPath changes that. We combine three signals into one objective, evidence-based picture for the clinician.
One test. Three signals. One objective output
One test. Three signals. One objective output
Biology: a point-of-care biomarker panel
The biology is established. Our work is engineering it into a point-of-care test that runs inside a routine 10-minute appointment, validated metabolic signatures, operationalised for primary care.
Behaviour: a short digital check-in
A brief, structured check-in captures behavioural signal alongside the biological measurement, completed by the patient in minutes.
AI: agentic analysis
An agentic AI layer integrates both inputs into a single objective signal the GP can act on, built to fit existing workflows, not replace clinical judgement.
Building around the clinician, not the lab
Building around the clinician, not the lab
50+ GP interviews confirm the demand. NeuroPath is designed to add no time and no new workflow, an objective signal where before there was only subjective judgement, giving clinicians the evidence to act earlier, before crisis.
NeuroPath is initially built for primary care. A point-of-care test that runs inside a routine GP appointment, producing an objective signal to support clinical judgement, not replace it.
Today, a GP assessing a patient for anxiety, depression, or self-harm relies largely on what the patient reports and their own judgement in a ten-minute window. NeuroPath adds a measurable biological and behavioural signal to that moment, giving the clinician objective evidence to act on, earlier.
Aligned to NICE NG225. NeuroPath is designed to support the assessment framework set out in NICE guideline NG225, adding objective signal where guidance calls for structured clinical judgement.
Ethics-approved. The platform's clinical evaluation has received ethics approval.
In pilot. NeuroPath is being evaluated at NHS pilot sites in Cambridge.
Page updated
Google Sites
Report abuse